Recover Investment Losses: Class Action Initiated Against ARS Pharmaceuticals, Inc. (SPRY)
Levi & Korsinsky announced a securities class action against ARS Pharmaceuticals on behalf of investors in SPRY securities, alleging misleading statements between March 9 and June 24, 2026. The complaint centers on the company's guidance for expanded CVS Caremark insurance coverage of neffy, which failed to materialize by the guided July 1, 2026 deadline; CVS Caremark deferred its decision to January 2027. SPRY shares fell from $10.54 to $8.02 on the June 24 revelation, a one-day drop of about 23.9%.
Key figures
- Class period end
- June 24, 2026
- Stock close after
- $8.02
- Class period start
- March 9, 2026
- Stock close before
- $10.54
- One day stock decline
- 23.9%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.